[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] News articles from Diabetes in Control

Item #7
New Relief for severe, chronic, nausea and vomiting associated with

Enterra Therapy is indicated for the treatment of chronic nausea and
vomiting associated with gastroparesis when conventional drug therapies
are not effective.

Gastroparesis is a stomach disorder in which food moves through the
stomach more slowly than normal. In some patients, this condition results
in severe, chronic nausea and vomiting that cannot be adequately
controlled by available drugs. These patients have difficulty eating and
may require some form of tube feeding to ensure adequate nutrition.

Enterra Therapy uses mild electrical pulses to stimulate the stomach. This
electrical stimulation helps control the symptoms associated with
gastroparesis including nausea and vomiting.

For nearly 100,000 people in the United States who have gastroparesis,
stomach discomfort is a daily battle. In gastroparesis, stomach contents
do not move into the intestine quickly enough to be digested properly.
When there's a lot of food in the stomach, it gets distended, explained
Dr. Henry Parkman, director of Temple's gastrointestinal motility
laboratory. The distention causes abdominal discomfort, and people will
get nauseated because there is so much food in the stomach. For more info:

Item #9
Xenotransplantation unlikely to reduce organ shortage in near future

The possibility that diseases may be introduced into the general
population by xenotransplantation cannot be ruled out on the basis of
current evidence, a new report from the United Kingdom

Xenotransplantation Interim Regulatory Authority has concluded.
Xenotransplantation of whole organs, from cloned animals like the one
above, is unlikely to solve the problem of shortage of organs for
transplantation in the near future, as originally thought, it says. Long
term rejection is still a problem, and cloning and genetic modification
techniques to address this are still at an early stage.

The authority's third annual report said that while progress has been
made, and research into stem cell therapies to treat neurological
disorders, stroke, and diabetes is worth pursuing, "uncertainty about the
safety of xenotransplantation continues to be a significant obstacle."
Caroline White, London

Item #10
44th State to Pass laws Covering Diabetes Supplies, Equipment and

Governor Jim Geringer (R), signed into law yesterday the Insurance
Coverage for Diabetes Act (HB 185). This law ensures that affected Wyoming
health policies cover medically necessary and prescribed supplies,
equipment and education that are necessary for a person to control their

This bill was sponsored by Rep. "Teense" Wilford (R-Saratoga). Rep.
Wilford, who has diabetes, was a true champion of the bill. "Enabling
people to obtain and afford necessary diabetes supplies and services as
part of their basic health policy coverage will help save lives, and
prevent serious complications of diabetes such as amputations, blindness,
and kidney failure. As a result of the substantial need for this bill,
families affected by diabetes in Wyoming appreciate Gov. Geringer's
signing the bill," said Rep. Wilford. The bill passed in the House 43-16.
It passed the Senate by a margin of 20-10, where it was sponsored by Sen.
John Hanes. "Our combined efforts will make a real difference in the lives
of people in Wyoming who live with diabetes everyday," Rep. Wilford added.

The law requires insurance and managed care policies governed by the state
of Wyoming to cover and reimburse for necessary diabetes supplies,
equipment and self management education. Wyoming is the 45th state to
enact diabetes insurance reform.

To date, over 22,000 Wyoming residents have been diagnosed with diabetes,
while many thousands more remain undiagnosed. A leading cause of
blindness, kidney disease, heart disease and amputations, diabetes claims
the lives of more than 193,000 Americans each year and has recently been
described by the Centers for Disease Control and Prevention as an
epidemic. It is the country's sixth leading cause of death by disease.

The following states do not have coverage: OH, ND, MT, ID, DE, and AL

Item #11
Study Finds Vitamin E Effective In Helping Prevent Diabetic Heart Disease

Texas researchers have determined that Vitamin E can help reduce the risk
of heart failure in diabetics.

Tests showed that Vitamin E reduced the amount of inflammation in blood
vessels of the heart, according to a study. The study was conducted by
medical scientists at the University of Texas's Southwestern Medical
Center in Dallas.

Heart disease has been shown to be one of the most serious possible side
effects of diabetes. But when Vitamin E is consumed, the vitamin can enter
body cells that contribute to plaque in the blood vessels, researchers
said, and help reduce the swelling which can lead to heart illness, or
cardiovascular disease.

The antioxidant properties of Vitamin E are the key to reducing the
inflammation, the tests determined. Vitamin E, along with Vitamin C, are
known as effective antioxidants, fighting off free radicals which can
damage healthy body cells.

Researchers conducted a study of 75 patients who had Type 2 diabetes,
which is a common form of the disease. Test subjects received l,200
international units of Vitamin E daily, and all of the persons tested
showed a lowering of inflammation in their blood.

The test participants included both patients who were diabetic and had
heart disease and some who were neither diabetic nor had heart disease.
Blood tests were administered both before and after the study to determine
the effect of the Vitamin E intake on inflammation. SOURCE Foods for the

Item #12
LXN Corporation's Personal Data Management System Receives FDA Clearance

Web-enabled Data Management System Offers Patients Unique Opportunity For
Sharing Diabetes Testing History With Healthcare Professionals

LXN Corporation today announced the FDA clearance of its data management
system for use with its unique IN CHARGE(TM) Diabetes Control System. The
web-enabled, Windows(R) compatible, data management system is the first
direct-to-web cable designed to allow users to download their glucose and
GlucoProtein(R) (fructosamine) test results directly to a password
protected web-based graph and data management package. No software
purchase is needed and the data management system can plot or "chart" test
results for 12 weeks of data at any one time. Data can be stored for time
periods much greater than 12 weeks, allowing patients and physicians to
spot changing trends in a patient's glucose control. Patients will have
the flexibility to directly download their stored test results with the
use of a purchased data management cable or can manually enter their test
results directly on LXN's website, www.inchargenow.com, at no charge.

"Being web-enabled will allow patients to more easily share their test
results and trends with their healthcare professional," said David G.
Kelemen Jr., vice president of marketing for LXN Corporation. "Patients
can grant direct access to their personal profile to their healthcare
professional thereby facilitating often needed discussion."

The IN CHARGE Diabetes Control System is the only system to offer two
important tests for glucose control on one simple to use hand-held meter.
Controlling average blood sugar levels is a primary goal of different
therapies used in diabetes management. The IN CHARGE fructosamine home
test, introduced by LXN as the GlucoProtein(R) test, indicates the average
of continuous glucose changes over the prior two- to three-week time
period. In contrast, traditional glucose tests provide only a snapshot of
glycemic control at any one given moment in time and may not be enough to
detect changes in overall glucose control. For more info:
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml